Clinical Trial Update: The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial updating the effects of neoadjuvant metformin on tumour cell proliferation and progression in resectable pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: UNKNOWN